FDA official logo
GSRS logoPFDA official logo

LABAFENOGENE MARSELECOBAC

UNII:ABR4S53CKC
Type:INGREDIENT SUBSTANCE
Formula:
Preferred Substance Name:LABAFENOGENE MARSELECOBAC
GSRS Full Record:
ABR4S53CKC
i

  • Engineered bacterium derived from Escherichia coli Nissle 1917 (EcN) that has been designed to treat phenylketonuria (PKU) by consuming and converting phenylalanine (Phe) to the nontoxic metabolites trans-cinnamic acid (TCA) and phenylpyruvate (PP).
  • LABAFENOGENE MARSELECOBAC [USAN]
  • Labafenogene Marselecobac
  • SYNB-1934
  • SYNB1934
  • labafenogene marselecobac [INN]
  • recombinant live Escherichia coli strain Nissle 1917 (EcN) bacteria, genetically engineered as follows: a) Insertion across the genome of four copies of a modified phenylalanine ammonia lyase (mPAL) gene from Photorhabdus laumondii subsp. laumondii with mutations S92G, H133M, I167K, L432I, V470A under control of the LacI repressor/P tac inducible promoter. b) Insertion of one extra copy of the endogenous high affinity phenylalanine specific permease (PheP), under control of the LacI repressor/P tac inducible promoter. c) Insertion of the gene L-amino acid deaminase (LAAD), derived from Proteus mirabilis, under control of the endogenous AraC transcriptional regulator/P BAD inducible promoter. d) Deletion of the dapA gene, which renders bacteria cells auxotrophic unless supplemented with diaminopimelate (DAP) exogenously




UNII - ABR4S53CKC | UNII Search Service